Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator

Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator

While treatment options are available for hepatitis B virus (HBV), there is currently no cure. Anti-HBV nucleoside analogs and interferon-alpha 2b rarely clear HBV covalently closed circular DNA (cccDNA), requiring lifelong treatment. Recently, we identified GLP-26, a glyoxamide derivative which mod...

Full description

Bibliographic Details
Main Authors: Selwyn J. Hurwitz, Noreen McBrearty, Alla Arzumanyan, Eugene Bichenkov, Sijia Tao, Leda Bassit, Zhe Chen, James J. Kohler, Franck Amblard, Mark A. Feitelson, Raymond F. Schinazi
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Viruses
Subjects:
GLP-26
hepatitis B virus
capsid effector
cardiomyocytes
cynomolgus monkeys
pharmacokinetics
Online Access:https://www.mdpi.com/1999-4915/13/1/114

Internet

https://www.mdpi.com/1999-4915/13/1/114

Similar Items